Cortex in the Black for Last Fiscal Quarter

Cortex Pharmaceuticals Inc., Irvine developer of drug therapies for neurological and psychiatric disorders reported that it earned nearly $1.2 million, or 7 cents a share, in the fiscal fourth quarter, compared with a loss of $469,000, or 3 cents a share, a year earlier. Revenue for the three months ended June 30 more than quadrupled to $2.8 million from $690,000.

For the year, the company posted a loss of $197,000, or 1 cent a share, compared with a loss of $1.6 million, or 12 cents a share, the previous year. Revenue rose 72% to $5.5 million.